Yahoo Web Search

Search results

  1. 1 day ago · Dr. Guttman is considered one of the world’s leading experts in inflammatory skin diseases. At this year’s EAACI Congress, Dr. Guttman gave a speech on JAK inhibitors and skin biomarkers during the “New Horizons in Skin Disorders” session on May 31.

  2. 1 day ago · Dr. Guttman is considered one of the world’s leading experts in inflammatory skin diseases. At this year’s EAACI Congress, Dr. Guttman gave a speech on JAK inhibitors and skin biomarkers ...

  3. May 26, 2024 · Ludwig Guttmann, a pioneering neurologist who revolutionized the treatment of spinal cord injuries and founded the Paralympic Games, is a true icon of medical history. Born in 1899 to a Jewish family in what is now Toszek, Poland, Guttmann‘s path to international renown was marked by tremendous courage, compassion, and innovation in the face ...

  4. 1 day ago · Dr. Guttman is considered one of the world’s leading experts in inflammatory skin diseases. At this year’s EAACI Congress, Dr. Guttman gave a speech on JAK inhibitors and skin biomarkers ...

  5. May 8, 2024 · Ludwig Guttmann (born July 3, 1899, Tost, Germany [now Toszek, Poland]—died March 18, 1980, Aylesbury, Buckinghamshire, England) was a German-born English neurosurgeon who was the founder of the Paralympic Games. Guttmann earned a medical degree from the University of Freiburg in 1924 and subsequently became a leading neurosurgeon.

  6. 1 day ago · Emma Guttman-Yassky, MD, PhD, Waldman Chair of the Kimberly and Eric J. Waldman Department of Dermatology and Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai in New York City, received the Paul Ehrlich Award for Experimental Research at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual […]

  7. May 16, 2024 · To conduct this work, Dr. Guttman will lead a controlled trial of 76 children (6-17 years old) with alopecia affecting at least 50 percent of the scalp, who will be randomized 2:1 (dupilumab to placebo) for 48 weeks, followed by 48 weeks open-label dupilumab to all participants so everyone can benefit, and lastly 16 weeks follow-up, for a total ...

  8. People also ask

  1. People also search for